Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$212.37 USD

212.37
362,966

+1.59 (0.75%)

Updated Nov 5, 2024 02:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Align Technology (ALGN) Gains From New Alliances, Global Growth

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

Intuitive Surgical (ISRG) Gets FDA Nod for da Vinci's New Label

Intuitive Surgical (ISRG) announces the FDA clearance of revised da Vinci Xi and X Labeling on Radical Prostatectomy.

Indrajit Bandyopadhyay headshot

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

Masimo's (MASI) R&D activities raise optimism about the stock.

DexCom's (DXCM) G7 CGM System Now Connects to Apple Watch

DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.

Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

DexCom (DXCM) Declines on Potential Competition for Stelo (revised)

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.

Inari's (NARI) Expanding Product Portfolio Offsets Competition

Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.

DexCom (DXCM) Declines on Potential Competition for Stelo

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment

ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.

Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M

Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.

Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe

Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.

Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Strength in HSA Likely to Aid HealthEquity's (HQY) Q1 Earnings

Continued strength in HSA, aided by transfers of HSA Assets from BenefitWallet, is likely to have boosted HealthEquity's (HQY) top line in the fiscal first quarter.

Stryker (SYK) Issues Safety Notice for Its Total Knee System

Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.